Xiaotian Zhong,Amarnauth Shastrie Prashad,Ronald William Kriz,Tao He,Will Somers,Wenge Wang,Leo Joseph Letendre
申请号：
US16807375
公开号：
US20200230256A1
申请日:
2020.03.03
申请国别(地区):
US
年份:
2020
代理人:
摘要：
An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates； ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry； and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
